Aier Investment Group Strategically Invests in New Eyes Medical to Co-Forge a New Landscape in Ophthalmic Device Development

The cooperation between New Eyes Medical and Ireland Medical Investment Group Limited will provide New Eyes Medical with advanced experimental platforms and abundant clinical application scenarios from Ireland Medical Investment Group Limited, accelerating research and development as well as technological innovation, reducing R&D costs, shortening the R&D cycle, and enhancing product clinical applicability and competitiveness.

Founded in 2002, Aier Eye Hospital has established a medical network across Asia, Europe, and North America. It was listed on the Shenzhen Stock Exchange in China in 2009 (Stock Code: 300015). The company's branches in Europe and Southeast Asia are respectively listed in Madrid, Spain (CBAV.MC), and Singapore (SGX:40T). As of June 30, 2025, there are 976 Aier Eye Hospital-branded hospitals, eye centers, and clinics globally, including 807 in mainland China, 9 in Hong Kong, 1 in the United States, 141 in Europe, and 18 in Southeast Asia.

Aier Eye Hospital is awarded"Top Ten National Trusted Health Brands of 2024" and other honors, a globalized ophthalmic medical group,In the agreement"Preferential Procurement under Equal Conditions"The terms provide a clear and high-quality market entry point for New Eyes products into the Ireland system, allowing for rapid access to premium market channels, securing orders and revenue; reducing operational costs and enjoying the benefits of industrial cluster effects.

One of the key projects in this strategic cooperation nominated by Ireland Medical Investment Group Limited is to jointly advance the significant product under research by New Eyes Medical ——Phacoemulsification and Vitrectomy Integrated Machine MTP5000Research and Development and Registration Work。

The MTP5000 Phaco-Vitrectomy Integrated Machine combines ultrasonic emulsification and vitreous cutting functions, aiming to improve surgical efficiency, reduce operational difficulty, and provide a more integrated and safer equipment option for ophthalmic surgeries. It is expected to become a significant breakthrough in China-produced high-end composite surgical devices.

• Technology R&D Collaboration:Ireland Medical Investment Group Limited will open its experimental platform and clinical application resources to help New Eyes accelerate product iteration and technological breakthroughs.

• Supply Chain and Market Cooperation:Under the same conditions, the Ireland system will give priority to purchasing New Eyes products, providing them with a fast market access.

This strategic cooperation marks an important breakthrough in China's domestically produced ophthalmic medical device industry. In the future, both parties will jointly promote the localization of key equipment, reduce the industry's reliance on imported high-end devices, and further enhance the voice of "Made in China" in the international market.

New Eyes Medical will also rely on the global network and brand advantages of Ireland Eye Care to accelerate."Going Global" pace, truly achieving a full-chain win-win from technology to market, and from China to international.

Shanghai New Eyes Medical Group was established in April 2005, with a registered capital of 163 million yuan and stock code 430140. It is a comprehensive high-tech enterprise that provides medical institutions with digital equipment products, medical equipment digital system integration services, and medical information solutions. The company independently owns a research and development center and production base in Jiading District, Shanghai, covering an area of 12 mu and with a building area of 30,000 square meters. It is expected to be put into use by 2025, providing a solid foundation for the development of high-end products.

Let us jointly look forward to this collaboration further stimulating innovation vitality, boosting industry morale, and contributing greater value to the eye health cause in China and even globally!